Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Conjugate or complex includes bacterium or component thereof or substance produced by said bacterium

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424184100 - ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-MEDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC IMMUNOSUPPRESSOR, ETC.)

424193100 - Conjugate or complex

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20100119543USE OF SHIGELLA INVAPLEX TO TRANSPORT FUNCTIONAL PROTEINS AND TRANSCRIPTIONALLY ACTIVE NUCLEIC ACIDS ACROSS MAMMALIAN CELL MEMBRANES IN VITRO AND IN VIVO - The in vivo and in vitro use of Invaplex to transport materials, including functional proteins and biologically active nucleic acids, across eukaryotic cell membranes. The eukaryotic cells include a variety of cell types, e.g. insect, reptile, fish, mammal and tumor cells. The suitable materials for transport include biochemicals such as reporter molecules, antibiotics, biopharmaceuticals and carbohydrates including polysaccharides, lipopolysaccharides, polynucleotides, such as DNA and RNA, and glycoproteins and proteins including antigens, enzymes, antibodies, receptors and hormones. In addition, Invaplex enhances the immune response to DNA vaccines and also can function by itself as a vaccine against shigellosis.05-13-2010
20090196886VACCINE AGAINST NICOTINE ADDICTION - The present invention provides a hapten in the form of a novel nicotine derivative that may suitably be conjugated with an appropriate carrier to yield an effective vaccine against nicotine addiction. More particularly, the invention relates to a nicotine derivative of the following formula (I):08-06-2009
2011019508615-VALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE VACCINE COMPOSITION - The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of 08-11-2011
20100150956MULTICOMPONENT VACCINES - Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of 06-17-2010
20130078273Vault Compositions For Immunization - Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.03-28-2013
20130034580NOVEL FORMULATIONS WHICH STABILIZE AND INHIBIT PRECIPITATION OF IMMUNOGENIC COMPOSITIONS - The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit particulate formation (e.g., aggregation, precipitation) of immunogenic compositions which are processed, developed, formulated, manufactured and/or stored in container means such as fermentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like.02-07-2013
20130034579IMMUNOGENIC COMPOSITIONS AND RELATED METHODS - This disclosure relates to adjuvants for use in immunogenic compositions comprising at least one antigen and an aluminum compound comprising hydroxyl groups that has been treated with phosphate, carboxylate, carbonate, sulfate diphosphonate or a mixture of two or more of these compounds and methods of using these compositions for preventing and treating diseases are also provided.02-07-2013
20100104593MENINGOCOCCAL CONJUGATE VACCINATION - Conjugated meningococcal capsular saccharides will be introduced into immunisation schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. In the invention, tetanus toxoid is used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunising a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a tetanus toxoid carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunised with a tetanus toxoid.04-29-2010
20100040647VACCINE - The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus are provided02-18-2010
20100143399PROCESS FOR MANUFACTURING VACCINES - The present application discloses a method for making an immunogenic composition comprising an improved way of conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. In addition, the conjugate is mixed with a staphylococcal antigen. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.06-10-2010
20100143400Immunostimulatory Oligonucleotides - The invention relates to immunostimulatory oligonucleotides and methods of using immunostimulatory oligonucleotides to induce an antigen-specific immune response. The invention further relates to a vaccine that comprises an immunostimulatory oligonucleotide and an antigen, and comprises a pharmaceutically acceptable carrier. The immunostimulatory oligonucleotides of the invention, in some embodiments, include one or more modified linkage(s).06-10-2010
20100092509Hypo- and Hyper- Acetylated Meningococcal Capsular Saccharides - Capsular saccharides derived from serogroups W135 and Y of 04-15-2010
20100003276Methods for treating anthrax and inhibiting lethal factor - This invention relates to a method of inhibiting lethal factor (LF) or for treating anthrax and other conditions related to anthrax infection comprising co-administration of an effective amount of an LF inhibitor and a vaccine to a patient in need of such treatment. Such co-administration unexpectedly provides an effective immune response.01-07-2010
20090304734IMMUNOGENS FOR MENINGITIDIS-A VACCINES - An oligosaccharide useful for a Meningitidis A vaccine contains a first mannose unit having a spacer in the alpha configuration at C-1, which spacer is capable of conjugating to a protein, and which is connected to a second mannose unit through a 1,6-linkage which connects C-6 of the first unit to C-1 of the second unit, wherein the 1,6-linkage comprises a phosphonate. Related methods of making such compounds, analogous compounds, or intermediates thereof are also disclosed.12-10-2009
20090041802IMMUNOGENIC COMPOSITION - The present application discloses an immunogenic composition comprising 02-12-2009
20110008385Immunogenic composition - The present application relates to immunogenic compositions comprising staphylococcal PNAG and Type 5 and/or 8 capular polysaccharide or oligosaccharide from 01-13-2011
20130071428PEPTIDES, CONJUGATES AND METHOD FOR INCREASING IMMUNOGENICITY OF A VACCINE - The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease.03-21-2013
20120189654VACCINE - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent 07-26-2012
20120237542MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of 09-20-2012
20110142876CONJUGATED VI SACCHARIDES - Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM06-16-2011
20080248059Dimensional Analysis of Saccharide Conjugates with Gpc & Sec-Mals - GPC (gel permeation chromatography) and size exclusion chromatography with detection by multi-angle light scattering photometry (SEC-MALS) can be used to accurately measure molecular size and molar mass, respectively, of saccharide conjugates. The invention provides (a) a process for measuring the molecular size of a conjugated saccharide antigen within a sample, comprising a step of analyzing the sample by GPC, and (b) a process for measuring the molar mass of a conjugated saccharide antigen within a sample, comprising a step of analysing the sample by SEC-MALS.10-09-2008
20100266625Meningococcal and Pneumococcal Conjugate Vaccine and Method of Using Same - This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both 10-21-2010
20090162394VACCINE - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent 06-25-2009
20110287049PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES - Active immunotherapy methods for treating a human patient having an amyloid disease characterized by the presence of amyloid fibrils comprising islet amyloid polypeptide (IAPP).11-24-2011
20090010959Pneumococcal Polysaccharide Conjugate Vaccine - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent 01-08-2009
20090098156Regimens for immunisation with meningococcal conjugates - Multivalent meningococcal conjugate vaccines are administered according to a schedule in which at least one or two doses are administered to a patient aged between 0 and 12 months, and a further dose is administered to a patient aged between 12 and 24 months.04-16-2009
20100291138Vaccine - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen form 11-18-2010
20100291137METHOD FOR REFOLDING NEISSERIAL NSPA PROTEIN - The present invention provides an isolated refolded NspA protein, and a method of preparing it.11-18-2010
20100291136Pharmaceutical Liquid Composition of Botulinum Toxin With Improved Stability - Disclosed herein is a liquid pharmaceutical composition of 11-18-2010
20100266626ADJUVANTED GLUCANS - The use of beta-glucans as antigens for immunising against fungi is known. According to the invention, the beta-glucans are administered together with an adjuvant. The adjuvant improves the immune response. The glucan will usually be conjugated to a carrier. Suitable glucans include laminarin and curdlan.10-21-2010
20120034261NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to 02-09-2012
20100119544VACCINE - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from 05-13-2010
20120107346COMBINATION VACCINES WITH LOW DOES OF HIB CONJUGATE - Provided herein are combination vaccines comprising antigens for protecting a subject against at least diphtheria, tetanus, pertussis and Hib, wherein: (a) the antigen for protecting against Hib is a conjugate of a Hib capsular saccharide; (b) the concentration of the Hib conjugate in the vaccine is <15 μg/ml; and (c) the Hib conjugate has never been lyophilised.05-03-2012
20100278856BoNT/A PEPTIDES AND METHODSOF PREDICTING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAPY - The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.11-04-2010
20090297553Regimens for Immunisation With Meningococcal Conjugates - Multivalent meningococcal conjugate vaccines are administered according to a schedule in which a first dose is administered to a patient aged between 0 and 12 months, and a second dose is administered to the patient aged between 12 and 24 months.12-03-2009
20080274135Measuring Degree of Polymerisation for Meningococcal Capsular Saccharides That Contain Sialic Acid - The degree of polymerisation (DP) is an important parameter for analysis of saccharide antigens, particularly in glycoconjugates. The invention provides methods that can be used to measure DP for capsular saccharides, particularly for meningococcal saccharides e.g. from serogroups W135 and Y. A preferred method is based on reduction of terminal sialic acid residues on saccharides, with DP then being calculated by comparing the molar ratio of total sialic acid to reduced sialic acid.11-06-2008
20080286300Analysis of Saccharide Vaccines Without Interference - The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers). The method can be used to analyse total and free saccharide in conjugate vaccines and simplifies quality control of vaccines containing capsular saccharides from multiple serogroups.11-20-2008
20110206726COMBINATION VACCINE WITH ACELLULAR PERTUSSIS - The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by 08-25-2011
20100136045NOVEL SHIGELLA PROTEIN ANTIGENS AND METHODS - The present invention relates to protein antigens IcsP2 and SigA2 from 06-03-2010
20100209450VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent 08-19-2010
20090181049Capsular polysaccharide solubilisation and combination vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.07-16-2009
20090181048CANCER DRUG DELIVERY USING MODIFIED TRANSFERRIN - The present invention provides transferrin (Tf) conjugates of anti-cancer agents with increased cellular association and increased cellular internalization. The present invention also provides methods of treating cancer comprising administration of a Tf conjugate with increased cellular association to a subject with cancer. The present invention additionally provides methods of making, as well as screening for, Tf conjugates with increased cellular association or cellular internalization. The present invention also provides Tf conjugates with increased cellular association and internalization for delivering nucleic acids to cancer cells.07-16-2009
20110212125VACCINE FOR SHIGELLA - Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an 09-01-2011
20130216571Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine - The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria 08-22-2013
20110229513LPS Based Vaccines - The removal of the glycosidic phosphate from the reducing end of the derived LPS molecule creates an aldehydo functionality which causes the formation of an immunologically dominant neo-epitope. Conjugation to the reducing end of a carbohydrate molecule following removal of the glycosidic phosphate traps the reducing glucosamine residue in an open-chain form which surprisingly was found to dominate the immune response. We therefore modified our conjugation strategy to avoid this open-chain form, by utilising the amino functionality created by the isolated amidase activity from 09-22-2011
20090252759IMMUNOGENIC COMPOSITION - The present application relates to an immunogenic composition comprising at least 2 conjugates of 10-08-2009
20100015175Vaccine - The invention relates to a vaccine for the treatment of disease caused by 01-21-2010
20090117148Capsular Polysaccharides Solubilisation and Combination Vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.05-07-2009
20100189740MODIFIED POLYSACCHARIDES FOR CONJUGATE VACCINES - The present invention relates to methods of manufacture of immunogenic glycoconjugates, in particular for use in pharmaceutical compositions for inducing a therapeutic immune response in a subject. The immunogenic glycoconjugates of the invention comprise one or more oligosaccharides or polysaccharides that are conjugated to one or more carrier proteins via an active aldehyde group. Accordingly, the invention provides methods of making (i) unsaturated microbial N-acyl derivative oligosaccharides or polysaccharides; (ii) novel conjugates of unsaturated N-acyl derivatives; and (iii) glycoconjugate compositions comprising conjugate molecules of fragments of microbial unsaturated N-acyl derivatives that serve as a covalent linker to one or more proteins. The invention further encompasses the use of the immunogenic glycoconjugates pharmaceutical compositions for the prevention or treatment of an infectious disease.07-29-2010
20100239604VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES - The present invention relates to an immunogenic composition comprising 09-23-2010
20110059125ZWITTERIONIC IMMUNOMODULATORS FOR THE TREATMENT OF ASTHMA AND ALLERGY - Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo.03-10-2011
20100255026Methods and compositions relating to anthrax spore glycoproteins as vaccines - Disclosed are methods for preparing an anthrax spore glycoprotein complex vaccine. Also, disclosed compositions of an anthrax vaccine including a spore glycoprotein complex as the active agent. In certain embodiments, the vaccines are sufficient to protect against infection from 10-07-2010
20110027307ANTI-SEPSIS CONJUGATE VACCINE - The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to 02-03-2011
20130129776Broad Spectrum Vaccine Against Typhoidal and Non-typhoidal Salmonella Disease - The present invention is drawn to multivalent 05-23-2013
20130129777CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES - Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against 05-23-2013
20110236414 Bacterial Polysaccharide-Polypeptide Conjugate Compositions - The present invention relates to improved bacterial polysaccharide-polypeptide conjugate compositions, pharmaceutical compositions comprising such bacterial polysaccharide-polypeptide conjugate compositions, and the use of such compositions. Furthermore, the invention relates to the use of a combination of a peptide of the formula R09-29-2011
20130142822CONJUGATED VI SACCHARIDES - Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM06-06-2013
20090068220COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING URINARY TRACT INFECTIONS - The present invention relates to methods and compositions for treating urinary tract infections. In particular, the present invention relates to vaccines and immune modulators for treating urinary tract infections.03-12-2009
20130164325CERAMIDE-LIKE GLYCOLIPID-ASSOCIATED BACTERIAL VACCINES AND USES THEREOF - The invention is directed compositions and methods related to bacterial cells that are physically associated with ceramide-like glycolipids for use as antigen carriers for heterologous antigens. The invention further relates to methods of incorporating ceramide-like glycolipid to bacterial cell walls. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.06-27-2013
20110033494Anti-Infective Agents and Uses Thereof - The present invention is concerned with novel immunostimulant microparticle compositions and their use as anti-infective agents in the treatment of bacterial and viral infections.02-10-2011
20110020390MENINGOCOCCAL FHBP POLYPEPTIDES - fHBP is a protein in 01-27-2011
20110045015CONJUGATED BETA-1,3-LINKED GLUCANS - Glucans having exclusively or mainly β-1,3 linkages are used as immunogens. These comprise β-1,3-linked glucose residues. Optionally, they may include β-1,6-linked glucose residues, provided that the ratio of β-1,3-linked residues to β-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by β-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolysed to a suitable form prior to conjugation.02-24-2011
20110117123Multivalent Vaccine Composition With Mixed Carrier - The invention concerns a pharmaceutical composition for treating or preventing a certain number of infections caused by pathogenic agents such as bacteria, comprising as immunogen, one or several polyosides derived from one or several pathogenic agents. The polyosides are in the form of conjugates, coupled with a carrier protein. The composition contains at least two types of conjugates, each being at least characterised by a different protein carrier.05-19-2011
20100233201VACCINE COMPOSITION - The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide of 09-16-2010
20100183662VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition is provided comprising a multivalent 07-22-2010
20110097357BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS - The present invention is directed to a bioconjugate vaccine, such as an 01-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X—N—Z—S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.04-28-2011
20090269370VACCINES COMPRISING MULTIMERIC HSP60 PEPTIDE CARRIERS - The present invention provides improved vaccine compositions having enhanced immunogenicity and methods of using same. The compositions and methods include immunogenic conjugates containing peptide carriers derived from heat shock protein 60 (HSP60). The known synthetic peptide carrier, p458, provides significantly improved immunogenicity when provided as a multimeric conjugate comprising a plurality of peptide carrier units conjugated to each antigen. Cell vaccine compositions comprising antigen presenting cells loaded with multimeric p458 conjugates are also provided.10-29-2009
20110256172EPITOPE-TARGETED ANTHRAX VACCINE - Anthrax vaccine compositions comprise a segment of a PA toxin protein that stimulates a B cell immune response specific for a defined epitope on the protective antigen of 10-20-2011
20110150923MUCOSAL MENINGOCOCCAL VACCINES - The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of 06-23-2011
20080254057Combined Meningococcal Conjugates With Common Carrier Protein - Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimises the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunising a patient against a disease caused by 10-16-2008
20080254058Pharmaceutical Composition Comprising a Bacterial Cell Displaying a Heterologous Proteinaceous Compound - The present invention pertains to a composition for the manufacture of a medicament comprising living or dead bacteria with controlled amounts of surface-coupled proteins or proteinaceous compounds and a method for the preparation of the composition. The bacterium provides a multivalent heterologous protein display vehicle that may be used in the manufacture of vaccines or medicaments for delivery via the mucosa.10-16-2008
20080206276Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections - Immunogenic compositions and methods for eliciting an immune response against 08-28-2008
20110070259Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine - The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from 03-24-2011
20110256173CHEMICAL SYNTHESIS OF PHOSPHATIDYLINOSITOL MANNOSIDE GLYCANS FROM MYCOBACTERIUM TUBERCULOSIS - The efficient synthesis of phosphatidylinositol mono- to hexa-mannoside (PIM10-20-2011
20100297166Meningococcal Oligosaccharide Linked Polysaccharides and Diptheria Protein Conjucate Vaccine for All Ages - Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. 11-25-2010
20110052624Type 5 And Type 8 Capsular Polysaccharides Of Overproducing S. Aureus Strains - The invention relates to the type 5 and type 8 capsular polysaccharides produced by overproducing 03-03-2011
20100196417COMPOSITIONS COMPRISING A B SUBUNIT OF SHIGA TOXIN AND A MEANS STIMULATING NKT CELLS - The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDI capable of stimulating NK T cells; and to a pharmaceutical composition and a medicament comprising said composition.08-05-2010
20100196416 Vaccine - A typhoid vaccine using heat shock protein (Hsp) of 08-05-2010
20100196418UNIVERSAL CARRIER FOR TARGETING MOLECULES TO Gb3 RECEPTOR EXPRESSING CELLS - The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: 08-05-2010
20110189223VACCINE - The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion.08-04-2011
2012030150215-VALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE VACCINE COMPOSITION - The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of 11-29-2012
20120301501METHOD FOR SELECTING AND PRODUCING VACCINE COMPONENTS AND VACCINES BASED THEREON - The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and/or active immunisation against a microorganism that can be killed by opsonophagocytic cells. The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunisation against a microorganism. The invention describes three pneumococcal proteins SlrA, IgA1 proteinase, and PsaA, and their use as a vaccine component with or without PpmA. The invention also discloses the use of antibodies against said proteins for passive immunization and diagnosis.11-29-2012
20120301500ANTI-SEPSIS CONJUGATE VACCINE - The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to 11-29-2012
20120207781DIMENSIONAL ANALYSIS OF SACCHARIDE CONJUGATES WITH GPC & SEC MALS - GPC (gel permeation chromatography) and size exclusion chromatography with detection by multi-angle light-scattering photometry (SEC-MALS) can be used to accurately measure molecular size and molar mass, respectively, of saccharide conjugates. The invention provides (a) a process for measuring the molecular size of a conjugated saccharide antigen within a sample, comprising a step of analysing the sample by GPC, and (b) a process for measuring the molar mass of a conjugated saccharide antigen within a sample, comprising a step of analysing the sample by SEC-MALS.08-16-2012
20120009213Meningococcal And Pneumococcal Conjugate Vaccine And Method Of Using Same - This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both 01-12-2012
20090136541IMMUNOGENIC COMPOSITION - The present application discloses an immunogenic composition comprising at least 2 different 05-28-2009
20090130140Capsular Polysaccharide Solubilisation and Combination Vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.05-21-2009
20120128712VACCINE DIRECTED AGAINST PORCINE PLEUROPNEUMONIA AND A METHOD TO OBTAIN SUCH A VACCINE - The present invention pertains to a vaccine directed against porcine pleuropneumonia, comprising lipopolysaccharide, wherein the vaccine comprises a polymyxin to reduce symptoms of an endotoxic shock arising from the lipopolysaccharide. The invention also pertains to a method to obtain such a vaccine and a method for administering the vaccine to a subject animal.05-24-2012
20120135030Method of Producing Protein-Carbohydrate Vaccines Reduced in Free Carbohydrate - This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membrane while the carbohydrate is not. The conjugate is then desorbed from the membrane, yielding a solution that is substantially reduced in free carbohydrate.05-31-2012
20100172931Pharmaceutical Composition Containing the NMB1796 Protein - The present invention is related to field of medicine, particularly to the development of pharmaceutical composition containing the NMB1796 protein. The composition described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. The NMB1796 protein was identified as a 07-08-2010
20120171241ANALYSIS OF SACCHARIDE VACCINES WITHOUT INTERFERENCE - The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers). The method can be used to analyse total and free saccharide in conjugate vaccines and simplifies quality control of vaccines containing capsular saccharides from multiple serogroups.07-05-2012
20090060945Integration of meningococcal conjugate vaccination - Conjugated meningococcal capsular saccharides will be introduced into immunisation schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. It has been found that diphtheria toxoid and its derivatives (such as CRM197) can safely be used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunising a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or derivative thereof) carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunised with a diphtheria toxoid (or derivative thereof).03-05-2009
20120258132Vagal Nerve-Based Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a vagal nerve-based disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a vagal nerve-based disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a vagal nerve-based disorder, use of such TEMs in treating a vagal nerve-based disorder, and use of such TEMs and Clostridial toxins in treating a vagal nerve-based disorder.10-11-2012
20090017059Vaccine Comprising Streptococcus Pneumoniae Capsular Polysaccharide Conjugates - The present invention discloses an immunogenic composition comprising 01-15-2009
20090017060Cleavable Vaccine Compositions and Uses Thereof and Methods of Making and Using the Same - The invention relates to methods for making vaccines using linkages that are cleavable under lysosomal processing conditions, and vaccine compositions obtained therefrom. In some embodiments, the vaccines comprise a tumor antigen, an immunogenic carrier and a linker covalently linking the tumor antigen and the immunogenic carrier by a thio ether linkage. Vaccines of preferred embodiments can be used against a cellular proliferative disease that is characterized by the tumor antigen.01-15-2009
20080317775Bacterial Antigens and Uses Thereof - Novel enzymes, processes and antigenic structures useful in producing vaccines and compounds useful in combating gram-negative bacteria are described. Enzymes were isolated from the slime mould 12-25-2008
20120321660CONJUGATION PROCESS OF BACTERIAL POLYSACCHARIDES TO CARRIER PROTEINS - Process for conjugation of bacterial saccharides including 12-20-2012
20090117147VACCINES COMPRISING OUTER MEMBRANE VESICLES FROM GRAM NEGATIVE BACTERIA - The present invention relates to the field of vaccine formulation, particularly the field of novel adjuvant compositions comprising outer membrane vesicles (or blebs), and advantageous methods of detoxifying these compositions, and advantageous methods of use of such adjuvants.05-07-2009
20110159030MUCOSAL COMBINATION VACCINES FOR BACTERIAL MENINGITIS - A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against 06-30-2011
20110159029MEASURING DEGREE OF POLYMERISATION FOR MENINGOCOCCAL CAPSULAR SACCHARIDES THAT CONTAIN SIALIC ACID - The degree of polymerisation (DP) is an important parameter for analysis of saccharide antigens, particularly in glycoconjugates. The invention provides methods that can be used to measure DP for capsular saccharides, particularly for meningococcal saccharides e.g. from serogroups W135 and Y. A preferred method is based on reduction of terminal sialic acid residues on saccharides, with DP then being calculated by comparing the molar ratio of total sialic acid to reduced sialic acid.06-30-2011
20130171187GLUCAN-BASED VACCINES - Anti-glucan antibodies have been found to be protective against systemic fungal infection with 07-04-2013
20130171188IMMUNOGENIC COMPOSITION - The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example 07-04-2013
20130177588Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine - The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria 07-11-2013
20080199490Immunogenic Composition - The present application discloses an immunogenic composition comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of all the at least two further bacterial saccharide conjugates.08-21-2008
20120276137COMPOSITIONS AND METHODS FOR PREPARING STAPHYLOCOCCUS AUREUS SEROTYPE 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE IMMUNOGENIC COMPOSITIONS - The present invention relates to immunogenic conjugates comprising 11-01-2012
20100316666Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of 12-16-2010
20110274717POLYSACCHARIDE CONJUGATION WITH DETOXIFIED E. coli HEAT LABILE ENTEROTOXIN (LT) USED AS VACCINE - A detoxified recombinant 11-10-2011
20130122037Vault Compositions for Immunization - Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.05-16-2013
20110311577METHOD OF PRODUCING A VACCINE - The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatography material in the presence of detergent and high salt.12-22-2011
20110311576MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH NON-HIB VACCINES - An aqueous immunogen formulation is used to reconstitute a lyophilised component including conjugates of capsular saccharides from 12-22-2011
20110311575MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES - A liquid D-T-Pa component is used to reconstitute a lyophilised meningococcal component, thereby producing a combined vaccine.12-22-2011
20130189300CARRIER MOLECULE - The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a spr0096 antigen and a spr2021 antigen. spr0096 and spr2021 are 07-25-2013

Patent applications in class Conjugate or complex includes bacterium or component thereof or substance produced by said bacterium